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Background: Many women living with HIV (WLHIV) are co-infected with cytomegalovirus
(CMV), Toxoplasma gondii (T gondii), and/or hepatitis C virus (HCV). The rates of
congenital or perinatal transmission of these co-infections are not well defined in the
current era, when most WLHIV receive antiretroviral therapy (ART) during pregnancy.
Methods: Retrospective review of infants of WLHIV born between 2009–2019. Mothers
were screened for antibodies to CMV, T. gondii, and HCV; chronic HCV infection
was confirmed using plasma RNA PCR. Infants whose mothers had positive/unknown
serostatus were screened for CMV using urine or saliva DNA PCR or culture at ≤3 weeks
of life; T. gondii using serology at ≤1 month; and HCV using plasma RNA PCR at ≤6
months and serology at ≥12 months.
Results: The study included 264 infants from 255 pregnancies in 191 mothers. At
delivery, the median (IQR) CD4 count was 569 (406–748) cells/mm3 and plasma HIV
load was 0 (0–24) RNA copies/mL. Among 243 infants born to CMV-seropositive (209)
or CMV-missed serostatus (25) mothers, 163 (67.1%) were tested for CMV. Four infants
had CMV detected, resulting in a rate of congenital infection of 2.5%. Among 65 infants
from 54 (21.2%) pregnancies in T. gondii-seropositive women and 8 in women with
unknown T. gondii-serostatus, one acquired congenital toxoplasmosis in the setting of
acute maternal T. gondii infection. There were no episodes of vertical transmission from
mothers with latent toxoplasmosis. Among 18 infants from 13 (5.1%) pregnancies in HCV
RNA PCR-positive women and 4 in women with unknown HCV serostatus, there were
no congenital or perinatal HCV transmissions.
Conclusions: In a US cohort of pregnant WLHIV on ART, we identified high maternal
CMV seroprevalence and a high rate of congenital CMV infection. We did not identify any
congenital or perinatal transmissions of T. gondii or HCV among mothers who had latent
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or chronic infections. Our data support screening pregnant WLHIV and their infants for
CMV and suggest that the rates of congenital and perinatal T. gondii and HCV infections
among infants born to WLHIV on ART may be lower in the era of effective ART.
Keywords: HIV, cytomegalovirus, toxoplasmosis, hepatitis C, pregnancy, congenital, perinatal

INTRODUCTION

who acquire congenital or perinatal HCV are asymptomatic at
birth, but up to 80% develop chronic infection and hepatitis
(24). Because of the severe potential outcomes associated with
these infections, it is important to understand the epidemiology
of mother-to-child transmission and establish guidelines for
screening pregnant WLHIV and their infants. In this study, we
sought to describe the epidemiology of CMV, T. gondii, and
HCV maternal co-infections and rates of congenital and perinatal
transmissions in a contemporary cohort of pregnant WLHIV
treated with ART and residing in the US.

Many pregnant women living with HIV (WLHIV) are coinfected with other agents that establish chronic or latent
infection, such as cytomegalovirus (CMV), Toxoplasma gondii
(T. gondii), and/or hepatitis C virus (HCV). These infections
may be more commonly transmitted to the fetus or neonate in
the context of maternal HIV coinfection. The rates of congenital
and/or perinatal transmission of these co-infections are not
well defined in the current era, when few WLHIV are immune
suppressed as a result of widespread routine administration
of antiretroviral therapy (ART). Because there are no widely
accepted interventions to prevent congenital and/or perinatal
transmission from women with these chronic or latent infections,
screening may not be routinely performed during pregnancy.
Congenital CMV infection occurs either during acute/primary
maternal infection or reactivation of prior maternal infection.
Reactivation is responsible for the majority of congenital
CMV infections and occurs in both immune-competent and
immunosuppressed mothers (1). Transmission rates among
seropositive WLHIV have been reported as high as 2–6%,
although many of these studies were performed before maternal
ART was standard of care, and many infants acquired HIV, which
may have impacted CMV transmission (9–15). Transmission of
T. gondii to a fetus can occur either as a result of acute infection
during pregnancy or reactivation of latent toxoplasmosis, which
is rare and occurs only in immunocompromised women (16).
While maternal immune status correlates inversely with risk
of transmission, cases of congenital toxoplasmosis have been
described in infants of WLHIV with CD4 counts >200 and even
>500 cells/mm3 ; however, some reports do not specify whether
transmission resulted from acute or chronic maternal infection
(17). In pregnant women with detectable plasma HCV RNA,
transmission to the infant can occur during pregnancy (∼25%
of transmissions) or delivery (∼75% of transmissions) (20). In
the US, routine testing of pregnant women for HCV is now
recommended, but it is unclear what proportion of pregnant
WLHIV are co-infected with HCV. In sum, there is a paucity
of recent data on the seroprevalence of these co-infections and
on congenital and perinatal transmission rates among WLHIV
treated with ART in the US.
When infants acquire these congenital or perinatal infections,
there can be potentially devastating consequences. Congenital
CMV and toxoplasmosis can result in severe ophthalmologic and
neurologic manifestations; congenital CMV is the leading nongenetic cause of sensorineural hearing loss in the United States
(US) (1). Most infants with congenital CMV are asymptomatic
at birth, but importantly, up to 15% of asymptomatic infants
develop hearing loss, and late onset and progressive hearing loss
can occur later in childhood (29, 30). Similarly, most infants
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MATERIALS AND METHODS
Study Design and Setting
In this retrospective cohort study, electronic health records were
abstracted (EHR, Epic systems, Verona, WI) for all pregnant
WLHIV followed by the Children’s Hospital Immunodeficiency
Program (CHIP) clinic between 1 August 2009 and 1 December
2019. The CHIP clinic is housed within Children’s Hospital
Colorado, a large tertiary care referral center in Aurora,
Colorado. CHIP manages the majority of pregnant WLHIV in
a 7-state region and follows HIV-exposed infants for the first
12–18 months of life. This study was approved by the Colorado
Multiple Institutional Review Board (COMIRB) with a waiver of
informed consent.

Data Collection and Management
Demographic and clinical data were abstracted from the EHR
and entered into standardized data collection forms developed
in REDCap, hosted by the University of Colorado, Denver (31).
EHR data included all available primary care, obstetric and
HIV specialty care encounters, inpatient notes and diagnostic
test results.

Study Population
All women received ART during pregnancy and were counseled
not to breastfeed. Infants received postnatal prophylaxis that
consisted of a minimum of 4 weeks of oral zidovudine; infants at
higher risk of HIV transmission received additional prophylactic
antiretroviral drugs for up to 6 weeks. All pregnancies that
resulted in a live birth during the study period were included.

Laboratory Testing
Viral load and CD4 testing was performed monthly during
pregnancy for WLHIV. “Entry” viral load and CD4 results were
defined as the first results available after conception and before
delivery. “Delivery” viral load and CD4 results were defined as
the results available closest to the date of infant birth, within the
range of 45 days prior to infant birth to 100 days after infant birth.
Infants were tested for HIV using RNA or DNA PCR at birth,
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TABLE 1 | Demographics of mothersa and infants during the study period.

2 weeks of age, 4–6 weeks of age, and 4–6 months of age. HIV
antigen/antibody test was performed at 12–24 months of age to
document sero-reversion.
Mothers were screened for co-infections using serologic
testing for CMV, T. gondii, and HCV at least once during
pregnancy, typically in the first or second trimester. Repeat
CMV screening was performed later in pregnancy for mothers
with a clinical illness that could be compatible with acute CMV
infection. Screening for T. gondii was not typically repeated in the
third trimester, as T. gondii is not endemic to the dry climate and
high elevation of the US mountain west; therefore, mothers were
at low risk for primary infection during pregnancy. In mothers
seropositive for HCV, active HCV infection was confirmed using
RNA PCR. Screening was repeated during each pregnancy except
for mothers known to be seropositive from prior pregnancies.
Infants of seropositive mothers or mothers with unknown
serostatus were screened for CMV using urine or saliva DNA
PCR or culture in the first 3 weeks of life, T. gondii using serologic
testing in the first month of life (with repeat testing at 4 months
and 12 months if initial IgG detectable), and HCV using RNA
PCR by 6 months of life and serologic testing after 12 months
of life.

Pregnancy characteristics
(N = 255)
Maternal birthplace

247
134 (52.5%)

Africa

78 (30.6%)

Latin America

22 (8.6%)

East and Southeast Asia

11 (4.3%)

Maternal race

2 (0.8%)
211

Black non-Hispanic

102 (40.0%)

Hispanic

54 (21.2%)

White non-Hispanic

42 (16.5%)

Other
Toxicology screen positive during
current pregnancy

Demographics are reported using descriptive statistics; medians
(interquartile ranges) for continuous variables or counts
(percent) for categorical variables. When calculating rates
of transmission, each mother-infant dyad was considered
an independent transmission opportunity. Ninety-five percent
confidence intervals for the binomial distribution were calculated
using the Clopper-Pearson exact method.

RESULTS
During the study period, 191 mothers had 255 pregnancies, 9 of
which were twin gestations, for a total of 264 live-born infants.
The demographics of the WLHIV and their infants are described
in Table 1. Most pregnancies (66.3%) occurred in women who
identified as non-white race and nearly half of pregnancies
(44.3%) occurred in women who were internationally-born.
Mothers generally had well-controlled HIV; at delivery the
median (IQR) CD4 count was 569 (406–748) cells/mm3 and
viral load was 0 (0–24) copies/mL. Only 8.2% of pregnancies
occurred in women who had ever met CDC criteria for Stage
3 HIV infection (AIDS). Nearly all (92.2%) pregnancies were
treated with ART for at least 12 weeks prior to delivery. Deliveries
occurred at a median of 38.4 (37.6–39.4) weeks gestational age; 48
(18%) infants were born preterm.

Median (IQR) or
count (%)

United States

Eastern Europe

Statistical Analysis

13 (5.1%)
255

23 (9.0%)

Maternal age at delivery (years)

255

30 (26–34)

Gravidity

252

2 (1–4)

Parity

253

1 (1–2)

CD4 count at entryb (cells/mm3 )

244

555 (387–780)

CD4 count at deliveryc (cells/mm3 )

173

569 (406–748)

Viral load at entryb (copies/mL)

248

25 (0–6105)

Viral load at deliveryc (copies/mL)

253

0 (0–24)

AIDS diagnosis ever

243

21 (8.2%)

Duration of any ART during
pregnancy (weeks)

255

36.4 (23–39)

ART received for at least 12 weeks
before delivery

255

235 (92.2%)

Adherence self-report

222

100% of doses

184 (72.2%)

75–100% of doses

26 (10.2%)

50–75% of doses

6 (2.4%)

<50% of doses

6 (2.4%)

Mechanism of delivery

251

Vaginal

119 (46.7%)

Assisted vaginal

3 (1.2%)

Cesarean
Twin gestation

129 (50.6%)
255

9 (3.5%)

Number
evaluable

Median (IQR) or
count (%)

Gestational age at delivery (weeks)

262

38.4 (37.6–39.4)

Infants born <37 weeks gestation

262

48 (18.3%)

Infant birthweight (grams)

260

3,014 (2,668–3,320)

Infant sex, male

264

135 (51.1%)

Infant characteristics (N = 264)

a Some

mothers are included more than once in the table; 191 women had 255
pregnancies. Including 9 twins, there were 264 live-born infants during the study period.
b Entry viral load and CD4 results were defined as the first results available after conception
and before delivery.
c Delivery viral load and CD4 results were defined as the results available closest to the
date of infant birth, within the range of 45 days prior to infant birth to 100 days after
infant birth.
AIDS, acquired immunodeficiency syndrome; ART, antiretroviral treatment; IQR,
interquartile range.

HIV Transmissions
One infant in this cohort acquired HIV in utero (0.37%).
The infant’s mother immigrated to the US from an African
country late in her pregnancy. Her first prenatal visit in the US
occurred at 38 weeks gestational age, when HIV infection was
diagnosed. The CD4 count was 445 cells/mm3 and viral load
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Among the 142 pregnancies in CMV-seropositive mothers
that did not result in congenital CMV transmission, the median
(IQR) CD4 count at delivery was 573 (437–738) cells/mm3 and
viral load was 0 (0–15) copies/mL. The median duration of ART
during those pregnancies was 37 weeks. There were 7 mothers
treated with fewer than 12 weeks of ART prior to delivery. One
of these mothers was the mother whose infant acquired HIV, who
received only 1 day of ART prior to delivery. The remaining six
women were either diagnosed with HIV late in pregnancy (n =
4) or had previously established HIV infection but were difficult
to engage in care (n = 2). All six pregnancies were treated with
ART (range of 2 to 11 weeks), and the HIV viral loads at delivery
ranged from 0 to 2,600.

was 47,000 copies/mL. The mother immediately initiated ART
and a scheduled cesarean section was performed the next day.
However, the infant had two detectable HIV DNA/RNA PCRs
performed on days of life 0 and 2, which established the diagnosis
of in utero HIV infection. All other infants in this cohort were
determined to be HIV-uninfected.

Cytomegalovirus Seroprevalence and
Transmissions
CMV-seropositive status was documented in 209 (82.0%)
pregnancies among WLHIV. CMV-seronegative status was
documented in 21 (8.2%) pregnancies, and missing status in 25
(9.8%) pregnancies. The majority of tests (82.9%) were performed
in the first or second trimesters. Three seropositive mothers
had detectable anti-CMV IgM antibodies during pregnancy.
One of these mothers, who was tested in the second trimester,
had a qualitatively positive, but not quantifiable whole blood
CMV DNA PCR. The other two mothers, who were tested in
the first and third trimesters, respectively, had high anti-CMV
IgG avidity, indicating that the primary infection had occurred
≥4 months before the diagnosis; one of these mothers had an
undetectable CMV DNA PCR and the other mother did not have
CMV DNA PCR performed. None of the mothers with detectable
anti-CMV IgM antibodies transmitted CMV to their infants.
Among 243 infants whose mothers were CMV-seropositive or
unknown, 163 (67.1%) infants had CMV test results available. Of
those, 4 infants had a detectable DNA PCR in the first 3 weeks of
life, resulting in a prevalence of congenital CMV of 2.5% (95% CI:
0.7–6.2%). The rate of congenital CMV transmission was 1.6% if
all of the infants with missing CMV test results were assumed
to have negative testing, and 2.6% if excluding all mothers and
infants with missing CMV test results.
Fourteen CMV-screened infants were the products of twin
gestation, of whom one infant had detectable CMV DNA in
urine. Both infants in the twin pair with discordant results were
tested for CMV twice in the first 3 weeks of life; one infant was
repeatedly positive and the other infant was repeatedly negative.
Of the 4 infants with congenital CMV, all mothers received
ART during pregnancy. Two mothers received ART continuously
from prior to conception until after delivery. Both of these
mothers had undetectable viral loads throughout pregnancy
except for 1 “blip” in each mother to <100 copies/mL and
subsequent viral suppression. A third mother initiated ART in the
2nd trimester of pregnancy and her viral load quickly suppressed
and remained undetectable thereafter; her CD4 count was 64
cells/mm3 early in pregnancy and 197 cells/mm3 at delivery.
The fourth mother was difficult to engage in prenatal care due
to substance dependence and incarceration. She initiated ART
2 weeks prior to delivery. At delivery, her viral load was 1,000
copies/mL and her CD4 count was 180 cells/mm3 . All 4 infants
were asymptomatic at birth. One infant failed a newborn hearing
screen, but subsequent hearing evaluations were normal. This
infant, who was exposed to substances in utero and born at
36 weeks gestational age, was diagnosed with developmental
delay that required physical and occupational therapy. Another
infant, whose newborn hearing screen was normal, developed
mild hearing impairment later in life. None of these 4 infants
were treated with antivirals directed at CMV infection.
Frontiers in Pediatrics | www.frontiersin.org

Toxoplasma Gondii Seroprevalence and
Transmissions
T. gondii-seropositive status was documented in 54 (21.2%)
pregnancies among WLHIV. T. gondii-seronegative status was
documented in 193 (75.7%) pregnancies and missing status in 8
(3.1%) pregnancies. The majority of tests (77.4%) were performed
in the first or second trimesters. One seropositive mother,
described below, had evidence of acute T. gondii infection
during pregnancy.
Among 65 infants whose mothers were T. gondii-seropositive
or unknown, 50 (76.9%) had T. gondii test results available. Of
those, congenital toxoplasmosis was diagnosed in one infant
who was born to the mother with acute T. gondii infection.
The remaining 49 infants had negative serologic testing; there
were no known cases of reactivation of latent toxoplasmosis with
transmission to the fetus. Assuming binomial variation, the upper
confidence limit of the estimate of 0 T. gondii transmissions
is 5.5%.
The infant who acquired congenital toxoplasmosis is the
same infant who acquired HIV in utero, described above.
This infant’s mother had a T. gondii serologic panel sent
during her hospitalization for cesarean delivery. The results
became available after the mother and infant were discharged
home, and demonstrated detectable maternal anti-T. gondii
IgM, IgA, and IgG, indicating recent infection. The infant was
subsequently tested, and also had detectable anti-T. gondii IgM,
IgA, and IgG. The infant’s workup was notable for intracranial
calcifications and chorioretinitis. Hearing evaluation was normal.
The infant initiated treatment with pyrimethamine, sulfadiazine,
and leucovorin on day of life 20. Medications directed against T.
gondii were continued for the first year of life, with the exception
that pyrimethamine was held several times and the sulfadiazine
was briefly replaced with clindamycin around 3–4 months of
age, due to drug-induced neutropenia. The infant’s growth,
development, and neurologic exam were normal at age 3 years,
when the family relocated outside of the CHIP referral region.

Hepatitis C Seroprevalence and
Transmissions
HCV-seropositive status was documented in 16 (6.3%)
pregnancies among WLHIV. HCV-seronegative status was
documented in 235 (92.2%) pregnancies, and missing status
in 4 (1.6%) pregnancies. The majority of tests (80.0%) were
4
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We did not identify any congenital or perinatal transmissions
of T. gondii or HCV among HIV-exposed infants whose mothers
were virologically suppressed on ART. The one congenital
toxoplasmosis case in our cohort occurred in the setting of acute
maternal T. gondii infection in a mother with uncontrolled HIV
replication. This infant acquired both congenital toxoplasmosis
and in utero HIV infection; these two infections have been
previously described to occur simultaneously and having one in
utero infection may increase the risk of acquiring the other (32).
If this mother had presented to care earlier in pregnancy, her HIV
and toxoplasmosis could have been treated, and transmission of
these infections to the infant could potentially have been avoided.
Importantly, acute T. gondii infection during pregnancy
is a high risk scenario for fetal infection, and transmission
in this setting occurs in both immune-competent and
immunosuppressed mothers. In contrast, reactivation of
latent toxoplasmosis and transmission to the fetus is rare, but
has been reported in WLHIV. Congenital transmission of
toxoplasmosis from a seropositive WLHIV is estimated to occur
at a rate of <4% (17–19). While we identified zero transmissions
among the 65 infants at risk in our cohort, the upper confidence
limit of this estimate was 5.5%, which is consistent with the
previously reported rate. While our cohort was small, and only
21.2% of mothers were seropositive for T. gondii, our results
provide reassurance that congenital toxoplasmosis may occur
less frequently among WLHIV who are virologically suppressed
on ART than among WLHIV on less optimal treatment.
Similarly, we identified zero instances of congenital or
perinatal HCV infection among the 18 infants at risk in our
cohort, which suggests that maternal immune health may be
protective against transmission of HCV to the infants of WLHIV.
Mother-to-child HCV transmission has been estimated to occur
at a rate of 5–6% among women without HIV and 10–11% among
WLHIV; however, many studies in WLHIV were performed
before maternal ART was standard of care, and many infants
were co-infected with HIV (25–28). Importantly, the upper
confidence limit of our estimate was 18.5%, which is similar to
the previously reported rate of 10–11% among WLHIV (25). The
small number of women with chronic active HCV infection in
our cohort may have limited our ability to estimate congenital or
perinatal transmission rates.
Notably, the prevalence of 5% chronic HCV infections among
WLHIV in our cohort is much higher than the prevalence
reported for women of childbearing age in the US in general
(0.5–1%), and is similar to the prevalence identified in WLHIV
in another study from New York State (3.8%) (21–24). It is
important to obtain a precise estimate of the risk of HCV
vertical transmission in the context of maternal HIV co-infection.
Treatment of HCV infection during pregnancy is currently under
investigation and may become available in the next few years.
However, due to the small number of pregnancies complicated
by chronic HCV infection, it will take many years to gather data
on the risk of infant toxicity and congenital defects that may be
associated with the use of anti-HCV medications in pregnancy.
Moreover, infants born to women with HIV are already exposed
to ART in utero, which carries its own risks of toxicity (33). Thus,
the benefit of HCV treatment during pregnancy will need to be

performed in the first or second trimesters. Among the HCVseropositive mothers, 13 pregnancies occurred in women with
detectable RNA PCR, resulting in a prevalence of chronic active
HCV infection of 5.1% in this cohort.
There were no known congenital or perinatal transmissions
of HCV. Among 18 infants whose mothers had detectable HCV
RNA PCR or had unknown HCV status, 14 (77.8%) had HCV
test results available, all of whom had negative results. Assuming
binomial variation, the upper confidence limit of the estimate of
0 HCV transmissions is 18.5%.

DISCUSSION
In this US cohort of pregnant WLHIV treated with ART,
the majority of whom had well-controlled HIV, we identified
high maternal CMV seroprevalence (82%) and a high rate of
congenital CMV infection (2.5%). CMV seroprevalence among
women of childbearing age varies from 50% in high-income
countries to >95% in low and middle-income countries (2,
3). Within high-income countries, seroprevalence correlates
with nonwhite race, internationally-born status, and lower
socioeconomic backgrounds; some studies have also shown
higher seroprevalence among people living with HIV than in the
general population (3–5). In areas with near-universal maternal
CMV seroprevalence, the incidence of congenital CMV is 6–
8 per 1,000 infants, resulting in a mother-to-child transmission
rate of <1% (6–8). In our cohort of WLHIV, congenital CMV
infection occurred at a more than 2-fold higher rate than is
observed in the general population. Of note, approximately onethird of infants at risk for congenital CMV did not have test
results available. Even if all of the infants whose test results were
missing had negative testing for CMV, we would have identified
4 transmissions among 243 infants at risk, which would have
resulted in a rate of congenital CMV of 1.6%, still higher than
is observed in the general population. It is important to note that
the lower limit of our 95%CI for CMV transmissions was 0.7%,
which is similar to the rate of 0.6–0.8% described in highly CMVseropositive, HIV-uninfected populations (6–8). In addition, two
infants with congenital CMV were born to women who initiated
ART late in pregnancy; therefore, it is possible that transmission
rates may be lower among WLHIV who are virally suppressed
on ART prior to conception. Still, our results are in agreement
with prior reports that WLHIV are more likely to reactivate and
transmit CMV to their infants than women without HIV (9–15).
Among the 4 cases of congenital CMV in our cohort, only
one developed sequelae attributed to CMV infection. This infant
developed mild hearing loss after the newborn period, which did
not require any intervention. Another infant had developmental
delay requiring therapies, but was substance-exposed in utero
and born late-preterm, which precluded the attribution of defects
to a direct effect of CMV. All four CMV transmissions in our
cohort occurred as a result of reactivation of latent maternal
CMV infection. We identified three mothers with detectable antiCMV IgM antibodies concerning for acute CMV infection during
pregnancy, but two of these mothers had high anti-CMV IgG
avidity, which decreases the likelihood that their CMV infection
was acute.

Frontiers in Pediatrics | www.frontiersin.org
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in the US, and no congenital or perinatal transmissions of T.
gondii or HCV among HIV-exposed infants whose mothers were
on ART during pregnancy. Our data support screening efforts of
pregnant WLHIV and their infants for CMV and underscore the
need for additional studies on transmission of T. gondii and HCV
in this population.

weighed against the risk of in utero drug exposure, especially
among the population of WLHIV. Importantly, people with
HIV should be screened for HCV and treated, if appropriate,
as soon as the diagnosis of HIV is established (34). Thus, the
decision to treat HCV during pregnancy in WLHIV only applies
to those in whom the diagnoses of HIV and HCV are made
after conception.
Our results support screening of pregnant WLHIV and their
infants for CMV. The Department of Health and Human Services
(HHS) recommends screening only HIV-exposed infants whose
mothers had acute CMV infection during pregnancy and infants
with in utero HIV infection, with an added consideration
for screening all HIV-exposed infants because in utero HIV
transmission is often not ruled out during the window for
congenital CMV testing (in the first 3 weeks of life) (35). Our data
suggest that HIV-exposed, uninfected infants are at increased
risk of congenital CMV, so screening them may be warranted
even if HIV infection has been ruled out. Infants who are
identified as having congenital CMV should be followed closely
and evaluated for hearing loss at 6 month intervals, even if
they are asymptomatic and have a normal hearing evaluation at
birth (35).
The HHS recommends routine screening of pregnant WLHIV
for latent T. gondii infection and antimicrobial prophylaxis
against toxoplasmosis in seropositive WLHIV whose CD4 counts
are <100 cells/mm3 (35). Routine screening for HCV is indicated
for all people living with HIV upon entry to care (34). In
addition, screening of all pregnant women for HCV has been
recommended in the US since 2019, and has been shown to
be cost-effective when the prevalence of HCV is ≥0.03% (36,
37). While we are in agreement with screening for both of
these infections in pregnant WLHIV, we note that the rates of
congenital and perinatal T. gondii and HCV infections among
infants born to WLHIV who are virologically suppressed on ART
may be lower than previously described.
Limitations of this study include its retrospective nature
and accordingly, the substantial proportion of mothers and
infants who had missing data. We may have underestimated
transmission rates for CMV by including infants of mothers with
missing serologic screening results in the “at risk” group. The
total number of pregnancies included in the study was relatively
small, which limited our ability to identify congenital or perinatal
infections and resulted in wide confidence intervals around our
estimates of transmission, especially for T. gondii and HCV. In
addition, this study was performed at a single site, which may
limit the generalizability of our results. However, our cohort
included a diverse group of mothers and infants that is likely
to be representative of the demographics of pregnant WLHIV
managed at other urban US hospital-based clinics.
In conclusion, we identified a high rate of congenital CMV
among infants born to WLHIV treated with ART and residing
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